H.Lundbeck A/S Collaboration

Sareum Holdings PLC
19 January 2006


For immediate release                                            19 January 2006

                              SAREUM HOLDINGS PLC
                          ("Sareum" or the "Company")

      Sareum Announces Collaboration with Top 50 Pharma* - H. Lundbeck A/S

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery
and services business, is pleased to announce that it has entered into a
collaborative agreement with H. Lundbeck A/S (Copenhagen: LUN), an international
pharmaceutical company with sales of approx. €1.3 Billion in 2004, to provide
protein structure determination capabilities to accelerate drug discovery
research at Lundbeck. Sareum will apply its skills in high throughput protein
expression, purification and structure determination to explain the exact nature
of the interaction of Lundbeck's potential drug candidates with their target
protein receptor.

This information is invaluable in helping Lundbeck's scientists to develop new
and improved therapeutics to help patients suffering from neurological
conditions such as Alzheimer's disease, one of Lundbeck's key drug discovery
focus areas.

In return, Sareum will receive research fees and success milestone payments, the
majority of which are expected to be recognized in the financial year to June
2006. Financial terms of the agreement were not disclosed.

This is the third announcement relating to the trading update issued by Sareum
on 5th January 2006 where Sareum stated that it had entered into several
collaborations in late December, one of which is with Lundbeck.

Commenting on the agreement, Sareum's Chief Executive Officer, Dr Tim Mitchell,
said: "We are very pleased that Lundbeck has selected to work with Sareum as
their partner in protein structure determination. This is a further important
collaboration that Sareum has entered into with another top 50 international
pharmaceutical company, and we look forward to successful delivery of this
project to Lundbeck."

Commenting on the agreement, Lundbeck's Vice President of Research, Dr. Peter
Hongaard Andersen, said: "Structure based drug design is an important aspect in
modern drug discovery strategies and we expect this collaboration with Sareum
will enhance our Drug Discovery process. The partnership also further
illustrates Lundbeck's commitment to accelerating the discovery of novel
therapies for patients suffering from neurological and psychiatric diseases."

* By 2004 Global Pharma Sales


For further information:

Sareum Contacts:
Sareum Holdings                                           01223 497700
Tim Mitchell, Chief Executive Officer

Buchanan Communications                                   020 7466 5000
Tim Anderson, Mary-Jane Johnson


Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a specialist structure based drug discovery and services
business headquartered in Cambridge, UK. The Company was formed in August 2003
to discover new drugs for the treatment of cancer and to provide a range of drug
discovery services to the pharmaceutical industry. Sareum's unique approach aims
to halve the time it takes to discover new drug candidates.

Structure-based drug discovery involves the determination of a disease causing
protein's three-dimensional structure. Once the structure is known, novel
chemical entities are designed to 'lock-in' to the protein with the aim of
reversing or arresting a disease's progression.

Sareum's approach to structure based drug discovery is to produce multiple
recombinant proteins primarily through a baculovirus expression system;
determine their structure using x-ray crystallography; and then use its
innovative template-molecule x-ray screening technology to identify new chemical
entities designed to interact with the target protein. Sareum then uses its
high-throughput medicinal chemistry platform to rapidly synthesise further
molecules and develop the most promising into potential drug candidates.

Sareum provides its specialist drug discovery capabilities to partners in the
pharmaceutical and biotechnology industries. The Company aims to successfully
deliver: Programmes for complete gene-to-candidate structure-based discovery;
projects to accelerate or improve the productivity of specific activities; and
drug candidates for licensing at the Phase I or Phase II clinical trials stage.

Sareum joined the AIM Market of the London Stock Exchange in October 2004 and
trades under the symbol SAR. For further information, please visit
www.sareum.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange